Mammon Omicron SPAC Seeks $60M IPO Amidst High Dilution Risk

TL;DR

**Avoid Mammon Omicron's IPO; the immediate, massive dilution and sponsor incentives scream 'bad deal' for public investors.**

AI Summary

Mammon Omicron Acquisition Corp (MOAC) filed an S-1 for an initial public offering of 6,000,000 units at $10.00 per unit, aiming to raise $60,000,000. Each unit comprises one ordinary share and one right to receive one-eighth of an ordinary share upon business combination. The company is a blank check company, incorporated in the Cayman Islands, with no selected business combination target. MOAC has an 18-month window to complete an initial business combination. The sponsor, Mammon Cherry Limited, along with initial shareholders, acquired 1,725,000 ordinary shares for $25,000, resulting in an immediate and substantial dilution for public shareholders, with pro forma net tangible book value dilution ranging from 22.1% to 82.8% depending on redemption levels. The sponsor also committed to purchasing 207,625 private units for $2,076,250. Key risks include the potential worthlessness of founder shares and private units if no business combination is completed within 18 months, and significant conflicts of interest due to the sponsor's low cost basis and potential involvement in other SPACs.

Why It Matters

This S-1 filing signals another blank-check company entering a crowded SPAC market, offering investors a chance to participate in a future, yet-to-be-determined acquisition. However, the substantial immediate dilution of up to 82.8% for public shareholders, coupled with the sponsor's nominal $0.014 per share cost basis, creates a significant risk-reward imbalance. This structure could incentivize the sponsor to pursue less optimal deals, potentially impacting investor returns and raising questions about fiduciary duties in the competitive SPAC landscape.

Risk Assessment

Risk Level: high — The risk level is high due to the immediate and substantial dilution of up to 82.8% for public shareholders, as detailed in the 'Dilution to public shareholders' table. Furthermore, the sponsor paid only $25,000 for 1,725,000 ordinary shares, or approximately $0.014 per share, creating a significant incentive for officers and directors to complete any business combination, even if it's unprofitable for public shareholders.

Analyst Insight

Investors should exercise extreme caution and likely avoid this IPO due to the severe dilution and potential conflicts of interest. The low cost basis for the sponsor creates an unfavorable risk profile for public shareholders, suggesting that capital would be better deployed in SPACs with more aligned incentives or in traditional, operating companies.

Financial Highlights

debt To Equity

N/A

revenue

N/A

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

N/A

eps

N/A

gross Margin

N/A

cash Position

N/A

revenue Growth

N/A

Executive Compensation

Key Numbers

• $60.0M — IPO Gross Proceeds (Targeted capital raise from the initial public offering of 6,000,000 units at $10.00 each.)
• 18 months — Business Combination Deadline (Timeframe from the effective date of the registration statement to consummate an initial business combination.)
• 1,725,000 — Founder Shares (Number of ordinary shares held by initial shareholders, acquired for $25,000.)
• $0.014 — Founder Share Cost (Approximate per-share price paid by initial shareholders, highlighting significant dilution for public investors.)
• 207,625 — Private Units (Number of units Mammon Cherry Limited committed to purchase in a private placement.)
• $2.08M — Private Unit Purchase Price (Total purchase price for the private units by the sponsor.)
• 22.1% — Minimum Dilution (Percentage of dilution to public shareholders in a 'no redemption' scenario without over-allotment.)
• 82.8% — Maximum Dilution (Percentage of dilution to public shareholders in a 'maximum redemptions' scenario with over-allotment exercised.)
• $500,000 — Sponsor Loan Repayment (Maximum amount to be repaid to the sponsor for offering-related and organizational expenses.)
• $10.00 — Unit Offering Price (Price per unit for the initial public offering.)

Key Players & Entities

• Mammon Omicron Acquisition Corp (company) — Registrant for S-1 filing
• Mammon Cherry Limited (company) — Sponsor of Mammon Omicron Acquisition Corp
• Chardan Capital Markets, LLC (company) — Underwriter for the IPO
• Jia Yan, Esq. (person) — Legal counsel from Pillsbury Winthrop Shaw Pittman LLP
• Joseph M. Lucosky, Esq. (person) — Legal counsel from Lucosky Brookman LLP
• U.S. Securities and Exchange Commission (regulator) — Regulatory body for the S-1 filing
• $60,000,000 (dollar_amount) — Target gross proceeds from the IPO
• $25,000 (dollar_amount) — Amount paid by sponsor for founder shares
• $0.014 (dollar_amount) — Per share cost for founder shares
• $2,076,250 (dollar_amount) — Purchase price for private units by sponsor

FAQ

Risk Factors

• Dilution from Sponsor Shares [high — financial]: The sponsor acquired 1,725,000 founder shares for $25,000 (approximately $0.014 per share). This low cost basis will result in substantial dilution for public shareholders upon the closing of the IPO, with pro forma net tangible book value dilution ranging from 22.1% to 82.8%.
• Worthlessness of Sponsor Investment [high — financial]: If Mammon Omicron Acquisition Corp fails to complete an initial business combination within the 18-month timeframe, the sponsor's investment in founder shares and private units will become worthless. This risk is exacerbated by the potential for extensions, which may not always be pursued or approved.
• Business Combination Deadline [high — operational]: The company has a strict 18-month deadline to complete a business combination. Failure to do so will result in the liquidation of the company and distribution of trust account funds to public shareholders, rendering founder shares and private units worthless.
• Redemption Risk [medium — financial]: A high number of public shareholders may redeem their shares, potentially preventing the company from completing a desirable business combination or optimizing its capital structure. This could lead to the company being unable to complete its initial business combination.
• Conflicts of Interest [medium — legal]: The sponsor's low cost basis in founder shares and private units, coupled with potential involvement in other SPACs, creates significant conflicts of interest. This could influence the sponsor's decisions regarding business combinations and extensions.
• Private Placement Dilution [medium — financial]: The sponsor's purchase of 207,625 private units for $2,076,250 at $10.00 per unit, in addition to founder shares, further contributes to the dilution experienced by public shareholders.

Industry Context

Mammon Omicron Acquisition Corp operates within the Special Purpose Acquisition Company (SPAC) sector, which has seen significant growth and subsequent scrutiny. SPACs provide an alternative route to public markets for private companies, bypassing traditional IPO processes. The competitive landscape is characterized by numerous SPACs seeking targets, leading to potential pressure on deal quality and valuation. Industry trends include increased regulatory oversight and a focus on specific sectors for target identification.

Regulatory Implications

As a Cayman Islands-domiciled entity, Mammon Omicron Acquisition Corp is subject to SEC regulations governing SPACs, including disclosure requirements under the Securities Act of 1933 and the Securities Exchange Act of 1934. The S-1 filing itself is a critical regulatory step. Potential future regulations targeting SPAC structures, sponsor compensation, and disclosure practices could impact the company's operations and the value of its securities.

What Investors Should Do

1. Review Sponsor Dilution
2. Evaluate Business Combination Strategy
3. Analyze Redemption Rights
4. Monitor Sponsor Conflicts

Key Dates

• December 2, 2025: S-1 Filing Date — Marks the initial public filing of the registration statement for the IPO.
• Effective Date of Registration Statement: IPO Commencement — The date on which the SEC declares the registration statement effective, allowing the IPO to proceed.
• 18 months from Effective Date: Business Combination Deadline — The timeframe within which the company must complete its initial business combination.

Glossary

Blank Check Company

A company formed to raise capital through an initial public offering (IPO) for the purpose of acquiring an existing company, without any specific target identified at the time of the IPO. (Mammon Omicron Acquisition Corp is structured as a blank check company, meaning its primary purpose is to find and merge with another business.)

Units

A security consisting of multiple components, in this case, one ordinary share and one right to receive one-eighth of an ordinary share. (The IPO is structured around the sale of these units, which combine equity and a potential future equity claim.)

Rights

A financial instrument that gives the holder the right, but not the obligation, to purchase or sell an underlying asset at a specified price on or before a certain date. In this case, it's a right to receive a fraction of an ordinary share. (Included in each unit, these rights represent a potential future dilution for existing shareholders if exercised.)

Founder Shares

Shares of common stock issued to the company's founders or initial investors at a nominal price before the IPO. (The 1,725,000 founder shares acquired by the sponsor at $0.014 per share represent a significant source of dilution for public investors.)

Private Units

Units purchased by the sponsor or other private investors concurrently with the IPO, typically at the same price as the public offering. (The sponsor's purchase of 207,625 private units for $2,076,250 contributes to the company's capital but also adds to the overall dilution.)

Redemption Rights

The right of public shareholders to demand that the company repurchase their shares at a specified price (usually the IPO price plus accrued interest) if a business combination is not completed or upon the consummation of a business combination. (These rights are a key feature for public investors in SPACs, providing an exit if they are dissatisfied with the proposed business combination or if no combination occurs.)

Trust Account

An account established by a SPAC to hold the proceeds from the IPO, which are typically invested in U.S. Treasury securities or money market funds. These funds are used for the business combination or returned to shareholders upon liquidation. (The funds in the trust account are crucial for the business combination and for providing a return of capital to public shareholders if the SPAC liquidates.)

Business Combination

The merger, share exchange, asset acquisition, or other similar transaction that a SPAC undertakes to combine with an operating company. (The successful completion of a business combination within the specified timeframe is the primary objective of Mammon Omicron Acquisition Corp.)

Year-Over-Year Comparison

This is the initial S-1 filing for Mammon Omicron Acquisition Corp, therefore, there are no prior filings to compare key metrics against. All financial data and risk factors presented are based on the current IPO registration statement.

Key Financial Figures

• $60,000,000 M — BJECT TO COMPLETION, December 2, 2025 $60,000,000 MAMMON OMICRON ACQUISITION CORP 6,000,0
• $10.00 — nit that we are offering has a price of $10.00 and consists of one ordinary share and
• $100,000 — st (net of taxes payable and less up to $100,000 of interest to pay dissolution expenses
• $2,076,250 — vate unit for a total purchase price of $2,076,250 (or $2,188,750 if the underwriters&rsqu
• $2,188,750 — total purchase price of $2,076,250 (or $2,188,750 if the underwriters’ over-allotme
• $25,000 — ior to this offering. Our sponsor paid $25,000 for an aggregate of 1,725,000 ordinary
• $0.014 — reholders was $25,000, or approximately $0.014 per share. Accordingly, you will experi
• $10,000 — llotment option is exercised in full) $10,000 per month, up to $180,000 For office
• $180,000 — sed in full) $10,000 per month, up to $180,000 For office space, secretarial, admini
• $500,000 — gement team for up to 18 months Up to $500,000 Repayment of loans made to us by our
• $8.89 — maximum redemptions Offering price of $8.89 included in the units (adjusted to excl
• $55,726,840 — gible book value after this offering by $55,726,840, or $64,749,340 if the underwriters exe
• $64,749,340 — after this offering by $55,726,840, or $64,749,340 if the underwriters exercise their over
• $5,000,001 b — t us to maintain net tangible assets of $5,000,001 because holders of our public shares may
• $5,000,001 — ur net tangible assets are greater than $5,000,001 either immediately prior to or upon con

Filing Documents

• mammonomicron_s1.htm (S-1) — 2063KB
• mammonomicron_ex4-4.htm (EX-4.4) — 64KB
• mammonomicron_ex10-1.htm (EX-10.1) — 61KB
• mammonomicron_ex10-3.htm (EX-10.3) — 97KB
• mammonomicron_ex10-4.htm (EX-10.4) — 57KB
• mammonomicron_ex10-6.htm (EX-10.6) — 47KB
• mammonomicron_ex10-8.htm (EX-10.8) — 32KB
• mammonomicron_ex10-9.htm (EX-10.9) — 19KB
• mammonomicron_ex23-1.htm (EX-23.1) — 5KB
• mammonomicron_ex99-1.htm (EX-99.1) — 4KB
• mammonomicron_ex99-2.htm (EX-99.2) — 4KB
• mammonomicron_ex107.htm (EX-FILING FEES) — 63KB
• ex23-1_001.jpg (GRAPHIC) — 25KB
• ex23-1_002.jpg (GRAPHIC) — 38KB
• ex23-1_003.jpg (GRAPHIC) — 22KB
• 0001829126-25-009598.txt ( ) — 2786KB
• mammonomicron_ex107_htm.xml (XML) — 20KB

From the Filing

As filed with the U.S. Securities and Exchange Commission on December 2, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MAMMON OMICRON ACQUISITION CORP (Exact name of registrant as specified in its constitutional documents) Cayman Islands 6770 N/A (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) [ ] (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices) Cogency Global Inc. 122 East 42nd Street, 18th Floor New York, New York 10168 United States (800) 221-0102 (Name, address, including zip code, and telephone number, including area code, of agent for service) Copies to: Jia Yan, Esq. Pillsbury Winthrop Shaw Pittman LLP Suite 3001, 30th Floor Jing An Kerry Center, Tower 2 1539 Nanjing Road West, Shanghai 200041 The People’s Republic of China Tel: +86 21-6137-7980 Joseph M. Lucosky, Esq. Lucosky Brookman LLP 101 Wood Avenue South, 5th Floor Woodbridge, NJ 08830 Tel. No.: (732) 395-4400 Fax No.: (732) 395-4401 Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of this registration statement. If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box. If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. Table of Contents Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer Accelerated filer Non-accelerated filer Smaller reporting company Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the registration statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine. Table of Contents The information in this preliminary prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted. PRELIMINARY PROSPECTUS $60,000,000 MAMMON OMICRON ACQUISITION CORP 6,000,000 Units MAMMON OMICRON ACQUISITION CORP is a blank check company incorporated in the Cayman Islands as an exempted company with limited liability for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities. We have not selected any business combination target, and we have not, nor has anyone on our behalf, initiated any substantive discussions, directly or indirectly, with any business combination target. Our efforts to identify a prospective target business will not be limited to a particular industry or geographic region. This is an initial public offering of our securities. Each unit that we are offering has a price of $10.00 and consists of one ordinary share and one rig

View Full Filing

View this S-1 filing on SEC EDGAR